<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00433732</url>
  </required_header>
  <id_info>
    <org_study_id>MT400-302</org_study_id>
    <nct_id>NCT00433732</nct_id>
  </id_info>
  <brief_title>To Evaluate the Safety and Efficacy of Trexima in the Acute Treatment of Migraine Headaches</brief_title>
  <official_title>A Double-Blind, Multicenter, Randomized, Placebo-Controlled Single Dose Study to Evaluate the Safety and Efficacy Opf Trexima in the Acute Treatment of Migraine Headaches</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>POZEN</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>POZEN</source>
  <brief_summary>
    <textblock>
      To determine the efficacy of the Trexima versus placebo as assessed by pain relief and the&#xD;
      incidences of photophobia, phonophobia and nausea at 2 hours after treatment as the primary&#xD;
      endpoints.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary objective of this study is to determine the efficacy of the Trexima versus&#xD;
      placebo as assessed by pain relief and the incidences of photophobia, phonophobia and nausea&#xD;
      at 2 hours after treatment as the primary endpoints. Another objective of this study is to&#xD;
      evaluate the efficacy of Trexima when compared to the individual components (sumatriptan and&#xD;
      naproxen sodium) using sustained pain-free as the endpoint. It is the intent that this study&#xD;
      be sufficiently powered to detect differences that are clinically meaningful and&#xD;
      statistically significant in order to meet both objectives.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2004</start_date>
  <completion_date>April 2005</completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Trexima will be evaluated for efficacy as an acute treatment for migraine based on its superiority over placebo at 2 hours for: a) pain relief (no or mild pain), b) incidence of photophobia, c) incidence of phonophobia and d) incidence of nausea.</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>a) sustained pain relief over 24 hours, b) sustained photophobia-free over 24 hours, c) sustained phonophobia-free over 24 hours, and d) sustained nausea-free over 24 hours.</measure>
  </secondary_outcome>
  <enrollment>1400</enrollment>
  <condition>Migraine Headaches</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sumatriptan</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>naproxen sodium</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  A subject will be eligible for inclusion in this study if all of the following&#xD;
             criteria apply:&#xD;
&#xD;
               1. Subject is a male or a female who is not pregnant or is not lactating. A female&#xD;
                  is eligible to enter and participate in this study if she is of&#xD;
&#xD;
                    -  Non-childbearing potential (i.e., physiologically incapable of becoming&#xD;
                       pregnant): or,&#xD;
&#xD;
                    -  Child-bearing potential, has a negative pregnancy test (urine or serum) at&#xD;
                       screen, and employs one of the following acceptable measures of&#xD;
                       contraception:&#xD;
&#xD;
                         -  Complete abstinence from intercourse from 2 weeks prior to&#xD;
                            administration of the investigational product, throughout the study,&#xD;
                            and for a time interval after completion or premature discontinuation&#xD;
                            from the study to account for elimination of the investigational drug&#xD;
                            (a minimum of 24 hours); subjects utilizing this method must agree to&#xD;
                            use an alternate method of contraception if they should become sexually&#xD;
                            active and will be queried on whether they have been abstinent in the&#xD;
                            preceding 2 weeks when they present to the clinic for randomized&#xD;
                            treatment; or&#xD;
&#xD;
                         -  Female sterilization (pregnancy test not required); or&#xD;
&#xD;
                         -  Sterilization of male partner; or implants of levonorgestrel; or&#xD;
&#xD;
                         -  Injectable progestogen; or&#xD;
&#xD;
                         -  Oral contraceptive (combined or progestogen only); or&#xD;
&#xD;
                         -  Any intrauterine device (IUD) with published data showing that the&#xD;
                            lowest expected failure rate is less than 1% per year (not all IUDs&#xD;
                            meet this criterion); or&#xD;
&#xD;
                         -  Any other method with published data showing that the lowest expected&#xD;
                            failure rate for that method is less than 1% per year.&#xD;
&#xD;
                         -  Barrier method only if used in combination with any of the above.&#xD;
&#xD;
               2. Subject is 18-65 years of age.&#xD;
&#xD;
               3. Subject's first migraine occurred prior to the age of 50 years.&#xD;
&#xD;
               4. Subject has at least a 6-month history of migraine with or without aura according&#xD;
                  to the International Headache Society criteria (see Appendix I).&#xD;
&#xD;
               5. Subject experienced an average migraine headache frequency of 2-6 moderate or&#xD;
                  severe attacks per month in the previous 3 months.&#xD;
&#xD;
               6. Subject is able to distinguish his/her migraine attacks as discrete from any&#xD;
                  other types of headaches.&#xD;
&#xD;
               7. Subject is willing and able to give written informed consent prior to entry into&#xD;
                  the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  A subject will not be eligible for this study if any one or more of the following&#xD;
             criteria apply:&#xD;
&#xD;
               1. Subject has received another investigational drug within the 4 weeks preceding&#xD;
                  this study, subject was discontinued from the MT400-303 POZEN study, or subject&#xD;
                  was enrolled in this study or the MT400-302 POZEN study previously.&#xD;
&#xD;
               2. Subject has any concurrent medical or psychiatric condition that may affect the&#xD;
                  interpretation of efficacy and/or safety data or which otherwise contraindicates&#xD;
                  participation in a clinical trial with a new chemical entity. This includes, but&#xD;
                  is not limited to, chronic unstable debilitating diseases such as HIV infection,&#xD;
                  multiple sclerosis, cancer, etc.&#xD;
&#xD;
               3. Subject has a clinically significant disorder that, in the opinion of the&#xD;
                  investigator, would result in the subject's inability to understand and comply&#xD;
                  with the requirements of the study.&#xD;
&#xD;
               4. Subject has a history, signs, or symptoms of ischemic cardiac, cerebrovascular,&#xD;
                  or peripheral vascular syndromes or other significant underlying cardiovascular&#xD;
                  disease.&#xD;
&#xD;
               5. Subject has a history of cardiac arrhythmias requiring medication or a history of&#xD;
                  a clinically significant electrocardiogram (ECG) abnormality that, in the&#xD;
                  investigator's opinion, contraindicates participation in this study.&#xD;
&#xD;
               6. Subject has a history of cerebrovascular pathology including stroke and/or&#xD;
                  transient ischemic attacks.&#xD;
&#xD;
               7. Subject, in the investigator's opinion, is likely to have unrecognized&#xD;
                  cardiovascular disease, based on history or the presence of risk factors (e.g.,&#xD;
                  hypertension, hypercholesterolemia, smoker, obesity, diabetes, strong family&#xD;
                  history of coronary artery disease, female with surgical or physiological&#xD;
                  menopause, or male over 40 years of age).&#xD;
&#xD;
               8. Subject has evidence or history of ischemic abdominal syndromes, peripheral&#xD;
                  vascular disease, or Raynaud syndrome.&#xD;
&#xD;
               9. Subject has uncontrolled hypertension at screening (sitting systolic pressure&#xD;
                  &gt;160 millimeters of mercury [mmHg], diastolic pressure &gt;95 mmHg).&#xD;
&#xD;
              10. Subject has a history of epilepsy or conditions associated with a lowered seizure&#xD;
                  threshold.&#xD;
&#xD;
              11. Subject has a history of basilar or hemiplegic migraine.&#xD;
&#xD;
              12. Subject has a history of impaired hepatic or renal function that, in the&#xD;
                  investigator's opinion, contraindicates participation in this study, or the&#xD;
                  subject has any other abnormal laboratory value of clinical significance for this&#xD;
                  study.&#xD;
&#xD;
              13. Subject has a history of non-migraine (i.e., tension type, sinus, etc.) headache&#xD;
                  frequency greater than or equal to 15 days/month in each of the 3 months prior to&#xD;
                  screening.&#xD;
&#xD;
              14. Subject has had &gt;6 migraine attacks/month in either of the 2 months prior to&#xD;
                  screening.&#xD;
&#xD;
              15. Subject is currently taking a monoamine oxidase inhibitor (MAOI), has taken an&#xD;
                  MAOI within the 2 weeks prior to screening, or plans to take an MAOI within 2&#xD;
                  weeks after treatment.&#xD;
&#xD;
              16. Subject is currently taking any anti-coagulant (e.g. warfarin) or NSAID (except&#xD;
                  doses of aspirin â‰¤ 325 mg per day, used for cardiovascular prophylaxis) on a&#xD;
                  regular basis.&#xD;
&#xD;
              17. Subject is currently taking or has taken in the previous 3 months, a migraine&#xD;
                  prophylactic medication containing ergotamine, an ergot derivative&#xD;
                  (dihydroergotamine), or methysergide.&#xD;
&#xD;
              18. Subject is currently taking or has taken in the previous 4 weeks, herbal&#xD;
                  preparations containing St. John's Wort (Hypericum perforatum).&#xD;
&#xD;
              19. Subject has hypersensitivity, intolerance, or contraindication to the use of&#xD;
                  sumatriptan or naproxen sodium, any of its components, or any other 5-HT1&#xD;
                  receptor agonist.&#xD;
&#xD;
              20. Subject has history of allergic reactions to naproxen preparations, including&#xD;
                  subjects in whom aspirin or other NSAID drugs induce the syndrome of asthma,&#xD;
                  rhinitis, and nasal polyps.&#xD;
&#xD;
              21. Subject is pregnant, actively trying to become pregnant, or breast-feeding.&#xD;
&#xD;
              22. Subject is of childbearing potential and not using adequate contraceptive&#xD;
                  measures.&#xD;
&#xD;
              23. Subject has a recent history (in the past 3 months) suggestive of alcohol or drug&#xD;
                  abuse or dependence, including overuse (abuse) of ergotamines and/or narcotics to&#xD;
                  treat migraines. Ergotamine abuse is daily use for 14 consecutive days or&#xD;
                  intermittent consumption exceeding 10 mg per week for any two weeks.&#xD;
&#xD;
              24. Subject has participated in an investigational drug trial within the previous&#xD;
                  four weeks or plans to participate in another study at any time during the period&#xD;
                  of this stu&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Taylor</last_name>
    <role>Study Director</role>
    <affiliation>POZEN</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Little Rock Family Practice Clinic</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pozen, Inc.</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27517</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2005</verification_date>
  <study_first_submitted>February 8, 2007</study_first_submitted>
  <study_first_submitted_qc>February 9, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 12, 2007</study_first_posted>
  <last_update_submitted>February 9, 2007</last_update_submitted>
  <last_update_submitted_qc>February 9, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 12, 2007</last_update_posted>
  <keyword>TREXIMA</keyword>
  <keyword>MIGRAINE HEADACHES</keyword>
  <keyword>Subjects may be enrolled if they are 18-65 years of age, have a demonstrated history of migraine headaches</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Migraine Disorders</mesh_term>
    <mesh_term>Headache</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Naproxen</mesh_term>
    <mesh_term>Sumatriptan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

